<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02989623</url>
  </required_header>
  <id_info>
    <org_study_id>15F.264</org_study_id>
    <nct_id>NCT02989623</nct_id>
  </id_info>
  <brief_title>Copper Cu 64 TP3805 PET in Detecting Prostate Cancer in Patients With Persistently Elevated PSA</brief_title>
  <official_title>A Pilot Phase I Open Label Study of Cu-64-TP3805 PET Imaging for Detection of Prostate Cancer in Men With Persistently Elevated PSA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot phase I trial studies how well copper Cu 64 TP3805 positron emission tomography
      (PET) works in detecting prostate cancer in patients with persistently elevated prostate
      specific antigen (PSA). The copper Cu 64 TP3805 PET scan uses copper Cu 64 TP3805, a compound
      made of a radioactive agent attached to a molecule that looks like a hormone that binds to
      cancer cells to detect prostate cancer during PET scans. Copper Cu 64 TP3805 PET may be able
      to see tumors at an earlier stage than the standard of care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the ability of Cu-64-TP3805 (copper Cu 64 TP3805) to detect prostate cancer
      (PC), or absence thereof, within the prostate gland.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2015</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate cancer detection within the prostate gland by copper Cu 64 TP3805 PET</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The proportion of lesions detected with copper Cu-64 PET will be determined with the lesion as the unit of analysis. 95% confidence intervals will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of multiple lesions in an individual patient</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Generalized Estimating Equations will be utilized.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Diagnostic (copper Cu 64 TP3805, PET/CT, biopsy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive copper Cu 64 TP3805 IV over 5 minutes and 30 minutes and 2 hours later, undergo whole body Positron Emission Tomography/Computed Tomography (PET/CT) imaging over 1 hour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Copper Cu 64 TP3805</intervention_name>
    <description>Given Intravenously</description>
    <arm_group_label>Diagnostic (copper Cu 64 TP3805, PET/CT, biopsy)</arm_group_label>
    <other_name>Cu-64-TP3805</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography and Computed Tomography Scan</intervention_name>
    <description>Undergo copper Cu 64 TP3805 PET/CT scan</description>
    <arm_group_label>Diagnostic (copper Cu 64 TP3805, PET/CT, biopsy)</arm_group_label>
    <other_name>PET/CT SCAN</other_name>
    <other_name>Positron Emission Tomography/Computed Tomography</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide signed informed consent and willingness to comply with protocol
             requirements

          -  Persistently elevated PSA

          -  Scheduled for magnetic resonance imaging (MRI) fusion/transrectal ultrasound (TRUS)
             biopsy, followed by histology

          -  Agree to use an acceptable form of birth control for a period of 7 days after the
             Cu-64-TP3805 injection

        Exclusion Criteria:

          -  Participating would significantly delay the scheduled standard of care therapy

          -  Administered a radioisotope within 10 physical half-lives prior to study drug
             injection

          -  Have any medical condition or other circumstances that, in the opinion of the
             investigator, would significantly decrease obtaining reliable data, achieving study
             objectives or completing the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madhukar Thakur, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Madhukar Thakur, PhD</last_name>
    <phone>215-503-7874</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhukar Thakur, PhD</last_name>
      <phone>215-503-7874</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.kimmelcancercenter.org</url>
    <description>Sidney Kimmel Cancer Center</description>
  </link>
  <link>
    <url>http://hospitals.jefferson.edu/</url>
    <description>Thomas Jefferson University Hospital</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2016</study_first_submitted>
  <study_first_submitted_qc>December 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2016</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Copper</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

